Ensuring product safety throughout the lifecycle is a critical regulatory obligation. While clinical trial data may be limited once a product receives marketing authorization, sponsors must continuously monitor, evaluate, and manage emerging safety information from multiple data sources. These include spontaneous adverse event reports, post-marketing studies, clinical research, published scientific literature, digital health data, to ensure ongoing benefit-risk assessment.
The Signal Management process encompasses the following key activities:
At CareLyft, our Signal Management activities are driven by a rigorous, medically led approach. Our dedicated team of healthcare professionals—including experienced physicians—conducts in-depth medical reviews and safety assessments under the close supervision of subject matter experts. This ensures scientifically robust, regulator-aligned outcomes. Our approach is enhanced by AI-powered algorithms that analyze complex drug-event associations across diverse data sources.
We adhere to globally harmonized and locally applicable regulatory requirements, supporting sponsors across the full signal management lifecycle—from multi-source signal detection to structured validation, analysis, and prioritization.
By combining scientific rigor, regulatory insight, and operational excellence, CareLyft enables sponsors to maintain continuous vigilance—ensuring patient safety while meeting evolving global and regional regulatory expectations.